**Uterine Cancer Pathways**

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number:</td>
<td>Treatment Start Date:</td>
</tr>
</tbody>
</table>

**Pathology:**

**Line of Therapy:**
- __Neoadjuvant/Pre-Op__
- __Adjuvant/Post-Op__
  - __1st Line__
  - __2nd Line__
  - __3rd Line__
  - __3rd Line+__
  - __Maint__

**Stage:**

**ECOG Performance Status:**

**ICD-10 Code:**

**Biomarkers/Characteristics:** (select all that apply)

- Estrogen Receptor: __Positive__ __Negative__
- Progesterone Receptor: __Positive__ __Negative__

### Adjuvant Therapy | Stage III-IV or High Risk Histologies

- __Carboplatin and paclitaxel__

### Recurrent /Metastatic | First and Subsequent Lines of Therapy (1st Line+)

- __Carboplatin and paclitaxel__
- __Cisplatin and doxorubicin (Adriamycin)__

---

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.